Drug intelligence / Profile preview

2b3-101 + trastuzumab

Development stage: Unknown
Lead developer: 2-BBB Therapeutics
Modality: Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

2b3-101 + trastuzumab is a combination therapy consisting of glutathione pegylated liposomal doxorubicin (2B3-101) and the monoclonal antibody trastuzumab. 2B3-101 is a brain-targeted formulation of doxorubicin encapsulated in glutathione pegylated liposomes, designed to enhance delivery across the blood-brain barrier and increase drug concentration in brain tumors. Trastuzumab is a monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2). This combination has been investigated primarily for HER2-positive breast cancer patients with brain metastases, aiming to leverage both cytotoxic chemotherapy and targeted anti-HER2 therapy. The mechanism involves DNA intercalation and topoisomerase II inhibition by doxorubicin (from 2B3-101), combined with HER2 receptor blockade by trastuzumab[1][4][8].

Other names: glutathione pegylated liposomal doxorubicin + trastuzumab

Targets

TOP2A (DNA topoisomerase II)ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on 2b3-101 + trastuzumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 2b3-101 + trastuzumab.

Explore the full profile